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IL-17 DRIVES COPPER UPTAKE AND ACTIVATION OF GROWTH PATHWAYS
IN COLORECTAL CANCER CELLS IN A STEAP4-DEPENDENT MANNER
EVAN MARTIN
ABSTRACT
Colorectal cancer is a disease characterized by abnormal, invasive cell growth
beginning in the colon or rectum. The third most common type of cancer worldwide,
approximately one million new cases of the disease are diagnosed across the globe
annually, resulting in an estimated 700,000+ deaths. One major risk factor associated
with development of colorectal cancer is the presence of chronic inflammation in the
large intestine, also known as colitis. Inflammation is a complex immune response
against harmful stimuli, characterized by symptoms including heat, redness, swelling and
pain. One important molecular mediator of this process is interleukin 17 (IL-17), a proinflammatory cytokine. While acute inflammation is a useful defensive response against
invading pathogens, the presence of chronic inflammation is associated with an increased
risk of tumorigenesis.
Colorectal cancer is frequently observed to metastasize from the colon to the
liver, the body’s largest storage site of copper, after which it becomes significantly more
difficult to treat effectively. Copper is a trace nutrient required by all living systems, due
to its ability to participate in one-electron exchange reactions, a vital mechanism of
ubiquitous biological processes. STEAP4, a cell membrane protein, is a copper
reductase.
In this thesis, data are presented that show that colon cancer cells in which
STEAP4 is overexpressed take up more copper from their environment than colon cancer
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cells in which STEAP4 is expressed normally. Additional data show that IL-17
stimulation, previously linked to colorectal cancer progression, increases copper uptake
by colon cancer cells. A mouse model experiment also shows that induction of colitis
mobilizes copper from the liver into systemic circulation. Further, it is shown that
overexpression of STEAP4 enhances activation of IL-17-mediated growth pathways that
have previously been shown to drive cancer progression. Finally, it is shown that colitisassociated colorectal cancer mice treated with a copper chelator may develop fewer
tumor nodules that untreated mice. Taken together, these data suggest that IL-17
signaling drives tumor progression through a STEAP4-dependent mechanism of copper
uptake. It is further suggested that lowering body copper levels through chelation therapy
could be an effective method of stopping colorectal cancer progression.
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CHAPTER I
GENERAL BACKGROUND
1.1 Copper and Biology
Copper is a transition metal characterized by its malleability and ductility, a
reddish-brown color, and high thermal and electrical conductivity. It has a valence
electron configuration of [Ar]3d104s1 and an atomic number of 29 with a standard atomic
weight of 63.546. Due to its electron configuration consisting of a fully filled d-shell and
a half-filled s-shell, copper may be found naturally in its elemental form, though it can
also be found in the form of various ores, such as sulfides, oxides, and
carbonates. Copper is also a metal of historical importance to human civilization, as it
was the first metal to be smelted from ore, as well as the first metal to be cast as mold and
to be alloyed with another metal, tin, to form bronze [1].
Copper is also a critical element to the process of life. An essential element that
is necessary for all living systems, including animals, plants, fungi, as well as bacteria,
copper plays a role in many different vital functions [2]. The reason for copper’s
biological importance lies in its ability to exist in two stable oxidation states —
specifically, 1+, also referred to as the cuprous state, and 2+, also referred to as the cupric
state. This property allows copper to mediate one-electron exchange reactions, which are

1

crucial components of nutrient metabolism, as well the “respiratory burst”, a free radicalmediated defense mechanism against infection [3]. Additionally, copper is a known
cofactor required for the proper functioning of dozens of metalloproteins [4]. This
capacity to participate in one-electron exchanges can be “double-edged sword” for
organisms relying on it however, as copper is both a potent generator and suppressor of
radical species [3].
1.2 Human Copper Metabolism and Homeostasis
As is the case with all other living things, copper is required for the survival of
humans as well. After intake, dietary copper, which typically exists in the cupric state,
must first be reduced to the cuprous state by membrane-bound metalloreductase proteins
found in the cells that line the duodenum, as well as the stomach, to a lesser extent
[5]. These reductases are known as the Six-Transmembrane Epithelial Antigen of
Prostate, or STEAP family of proteins. Another membrane protein, known as Duodenal
Cytochrome B, or DCYTB, has also been proven to function as a copper reductase in
vitro, although it is not currently known with certainty if it performs this function in vivo
[6]. After reduction to the cuprous state, copper is then transported from the intestinal
lumen into the enterocytes, primarily by Copper Transporter 1 (CTR1), as well as CTR2,
to a lesser extent [7]. It is important to note that upon copper uptake by a cell, the ion is
immediately bound by one of several carriers to prevent unwanted reactions with cellular
components, which may generate free radical species [8]. Some copper is bound in the
enterocyte by metallothionein (possibly after being delivered by glutathione, another
copper carrier), where it is then shuttled to several secondary carriers within the cell, and
eventually to its final destination. One these secondary carriers is known as Copper
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Chaperone Protein, or CCS, which in turn shuttles the copper ion to Cu/Zn Superoxide
Dismutase (SOD1), a protein necessary for the suppression of reactive oxygen species
within the cytosol [7]. Another is Cytochrome C Oxidase copper chaperone, also known
as COX17, which delivers copper to the mitochondria, where it is incorporated into
Cytochrome C Oxidase, a critical protein required for cellular respiration [8].

Figure 1.1 — Copper homeostasis in mammalian cells. Environmental copper, almost
always found in the cupric state, is first reduced by a reductase protein found on the
membrane of the cell, notably STEAP2, STEAP3, and STEAP4. After reduction, copper
is transported through the membrane by Copper Transporter 1 (CTR1) into the cytosol,
where it quickly binds to one of several chaperone proteins. CCS shuttles copper ions to
the radical-quenching enzyme superoxide dismutase 1 (SOD1). COX17 delivers the
copper ion to the mitochondria, where it can be incorporated into Cytochrome C Oxidase,
which participates in the electron transport chain. ATOX1 shuttles copper to the trans3

Golgi network, where it can be transported out of the cell to another destination in the
body. Additionally, copper ions may also bind to metallothionein or glutathione, which
store the ion while preventing it from oxidizing other components of the cell. Source:
Denoyer, D., et al. Targeting copper in cancer therapy: 'Copper That Cancer',
Metallomics. 2015; 7:1459-1476.
Most uptaken copper, however, is shuttled to the trans-Golgi network by
Antioxidant Protein 1 (ATOX1, also known as HAH1), where it is then taken up into the
Golgi body by a P-type ATPase known as ATP7A [9]. This ATPase is also referred to
Menkes’s Disease protein, or MNK, as it is the transporter that is dysfunctional in
patients suffering from the eponymous condition. Menke’s Disease is an X-linked
recessive disorder characterized by systemic copper deficiency due to an inability of
copper to be mobilized from enterocytes to the liver, and then on to its many destinations
around the body from there [2]. MNK is also the protein responsible for maintaining
normal copper levels in cells throughout the body, with the notable exception of the liver
cells known as hepatocytes. Another copper homeostasis-related condition, known as
Wilson’s Disease, is characterized by a similar mechanism in hepatocytes, in which the
corresponding P-type ATPase located on the Golgi bodies of the cells, known as ATP7B,
or Wilson’s Disease protein (WND), is defective, and therefore unable to excrete excess
dietary copper from the liver via the biliary pathway. Copper ions, in turn, accumulate in
the body’s tissues, notably the liver and nervous system, and cause deleterious effects [9].
In healthy individuals, however, after being shuttled by ATOX1 and taken up into
the trans-Golgi network by MNK, copper is then transported to the hepatic portal vein,
where it reaches the liver [10]. Upon being taken up by CTR1 into a hepatocyte, copper
ions follow largely the same pathways that they follow after being taken up by an
enterocyte, as described above. However, after being shuttled to the trans-Golgi network,
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hepatic copper ions then meet one of two fates – they may be sent to the biliary pathway
and excreted in the feces if levels of the element are higher than what the body requires;
or, copper ions may be bound by ceruloplasmin, another copper-carrying protein found
primarily in the blood, and then transported to the plasma for distribution around the
body [8]. Interestingly, several basic facts regarding optimal copper intake levels and
humans are still unclear [11], such as what percentage of copper from the diet is absorbed
(previously published studies have reported numbers between 12% - 71%), and whether
excess copper intake can increase the risk of various diseases (current evidence, though
far from conclusive, does not support the assertion that it does) [11]. This is largely
because modern humans eat quite varied diets, and it is therefore difficult to perform
sufficiently controlled experiments. It is additionally complicated by the lack of reliable
biomarkers of copper exposure at the current time [12].
1.3 The STEAP Family of Proteins
When found in nature, copper typically exists in the 2+ oxidation state, rather than
the less common 1+ oxidation state, or the elemental state. However, before a copper ion
can be taken up by a cell from its environment, the copper ion must be in the 1+
oxidation state. Thus, mammalian cells utilize a protein family known as the Six
Transmembrane Epithelial Antigen of Prostate, or STEAP, proteins. Three of these four
proteins, STEAP2, STEAP3, and STEAP4, have been identified as metalloreductases,
reducing extracellular iron ions from the 3+ (ferric) state to the 2+ (ferrous) state, and
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Figure 1.2 — Human copper metabolism. Copper ions are primarily absorbed into
enterocytes in the lining of the duodenum of the small intestine. It is then exported to the
hepatic portal vein, where it binds to one of several serum copper-binding proteins,
notably ceruloplasmin and albumin. From there, the ions can either be stored in the
hepatocytes of the liver, or exported to the bloodstream and other locations within the
body. Excess copper is exported into the bile by the liver, where it is then removed from
the body in the feces. Individuals with Menke’s Disease present with a defect in the
ATP7A protein, which leads to chronic copper deficiency. Individuals with Wilson’s
Disease suffer from a defect in the ATP7B protein, leading to copper overload in the
liver, which can cause many deleterious effects through Fenton chemistry, a common
mechanism mediated by copper or iron ions through which radical oxygen species can be
generated. Source: Van den Berghe, P., Klomp, L. New developments in the regulation of
intestinal copper absorption. Nutr Rev. 2009; 67(11): 658-672.

copper ions from the 2+ (cupric) state to the 1+ (cuprous) state, using NAD+ as an
acceptor. Expression of these proteins has been observed at the mRNA level on tissues
throughout the body, with the most robust expression on the fetal liver, prostate, brain,
pancreas, bone marrow, and placenta [13].
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Figure 1.3 — A schematic description of STEAP4’s protein structure and molecular
functions. STEAP4 is capable of reducing iron and copper ions, using NAD+ as an
acceptor. This function requires the ability to bind metal ions. It has also been reported
that STEAP4 exhibits phosphogluconate dehydrogenase activity, and is thus capable of
reducing 6-phosphogluconate to ribulose 5-phosphate, using NADP as a redox partner.
Source: Yoo, S., Cheong, J., & Kim, H. (2014). STAMPing into Mitochondria. Int J Biol
Sci, 10(3), 321-326.
1.4 Colorectal Cancer
The colon, also known as the bowel or large intestine, is the last part of the
digestive system in vertebrates, being immediately preceded by the small intestine. The
colon can be divided into several sections, beginning with most proximal and ending with
the most distal: cecum, appendix, ascending colon, transverse colon, descending colon,
sigmoid colon, rectum, and anal canal [14]. The large intestine serves to absorb water
and some nutrients from ingested food, and to move the indigestible matter along its tract
and store it until the material can be excreted as feces through the anus during
7

defecation. The colon is also home to a large community of bacteria, known as gut flora,
which subsist off of nutrients consumed by the host, and in turn aid in the process of
digestion [15].
Colorectal cancer is defined as a tumor, characterized by uncontrolled, abnormal
cell growth that may invade other tissues in the body, that begins in this part of the lower
digestive tract. The disease arises from colorectal polyps – small growths that form in the
lining of the colon and are typically benign when they are first formed. It is the third
most commonly diagnosed form of cancer worldwide [16], and the second leading cause
of cancer-related deaths in the United States [17]. The average risk of an individual
developing colorectal cancer in his or her lifetime is approximately five percent, however
this risk varies considerably between individuals based on several factors, including diet
and physical activity levels, tobacco usage, family history of the disease, heavy alcohol
use, and chronic intestinal inflammation (which will be discussed in more detail in a later
section) [18]. Globally, colorectal cancer accounts for approximately one in ten cancer
diagnoses [16], though it is significantly more common in Western countries, where it
accounts for around sixty-three percent of cancer diagnoses [19]. Both sexes are
approximately equally likely to be diagnosed with colorectal cancer, though men are
slightly more likely to be diagnosed with rectal cancer specifically [20]. Approximately
seventy-two percent of colorectal cancers originate in the colon, while the remaining
twenty-eight percent originate in the rectum [17]. The median age of diagnosis of colon
cancer is 68 for men and 72 for women, while for rectal cancer it is 63 years of age in
both men and women [17]. It is estimated that over 1.3 million Americans are currently
living with colorectal cancer [21]. Recently, it has been demonstrated that rates of
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colorectal cancer in young adults have been increasing between 1.0 – 2.4% annually in
adults between 20 and 39 years of age since the mid-1980s, and by 0.5 – 1.3% in adults
between 40 and 54 years of age since the mid-1990s [22].
The likelihood of survival and recovery from colorectal cancer is heavily
dependent upon the stage at which it is identified and diagnosed. Individuals diagnosed
with the condition in stages 1, 2 and 3 all have five-year survival rates above eighty-five
percent – by contrast, patients diagnosed at stage four, after distant metastases have been
established, the five-year survival rate is eleven percent [23]. Because of this, survival
rates from colorectal cancer have increased considerably in recent decades, rising from
around fifty percent to six-four percent from 1995 to 2000 alone [19]. This is largely due
to increased public awareness about the importance of regular screenings, which often
catch colorectal polyps before they become malignant at all [20]. Currently, around forty
percent of colorectal cancer cases are diagnosed in the local stages, compared to thirty-six
percent in the regional stage and twenty percent in the metastatic stage [17]. While
incidence of the disease has declined dramatically in the developed world over previous
decades however, significant disparities in outcomes remain for economically and
racially disadvantaged groups [24].
As mentioned earlier, many different factors influence an individual’s risk of
developing colorectal cancer. Some of these risk factors cannot be controlled, such as
age and genetic considerations. However, many colorectal cancer risk factors are
modifiable. One crucial variable that plays a role in this is diet. Diets rich in animal
products such as meat and fat have been implicated in the risk of developing these

9

Figure 1.4 — Stages of colorectal cancer. In Stage 0 CRC, the tumor has not grown
beyond the mucosal layer of the colon. In Stage 1 CRC, the tumor has grown through
mucosal layer of the colon into the submucosa. In Stage 2 CRC, the tumor has grown
into the muscular layer of the colon, but has not yet reached the surrounding lymph
nodes. In Stage 3 CRC, tumor cells have spread to the lymph nodes surrounding the
colon. Finally, in Stage 4 CRC, the primary tumor has metastasized and spread to other
organs. Source: https://www.webmd.com/colorectal-cancer/ss/slideshow-colorectalcancer-overview. For the National Cancer Institute © 2005 Terese Winslow LLC, U.S.
Govt has certain rights.
diseases [18]. Possible reasons for the link between animal product consumption and
colorectal cancer include the high iron content of red meat, a crucial nutrient for the
development and progression of cancers, as well as dietary fat creating an environment in
which gut flora capable of converting bile salts to carcinogenic N-nitroso compounds can
thrive [19]. Consumption of fruits and vegetables are believed to mitigate the risk of
colorectal cancer due to their high fiber content [25]. Another modifiable risk factor in
the development of the condition is tobacco usage – it is estimated that around one in
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eight cases of colorectal cancer deaths can be directly attributed to cigarette smoking
[26]. Cigarette smoking is known to increase the rates of formation and growth of
adenomatous polyps, which often develop into cancerous lesions [27]. Consumption of
large amounts of alcohol can also increase the risk of colorectal cancer development,
perhaps synergistically with tobacco smoking [28]. This has been suggested to be due to
the carcinogenic metabolites of alcohol, alteration of systemic hormone levels, changes in
folate metabolism, as well as alcohol-mediated oxidation of lipids and generation of
reactive oxygen species. There is also some evidence to suggest that alcohol can act as
solvent that increases the penetration of tobacco-derived carcinogens into colon mucosal
cells [19].
Another risk factor associated with incidence of colorectal cancer is obesity and
lack of physical activity. Indeed, many studies have demonstrated not only correlations
between excess body fat as well as a sedentary lifestyle with risk of developing colorectal
cancer, but also an inverse correlation between intensity and frequency of exercise
sessions and the individual’s risk of developing the disease [19]. The proposed reasons
for this relationship are numerous, and include increased gut motility, enhancement of
immune system function, decreasing levels of insulin and insulin-like growth factor,
decreasing body fat content, enhancing free radical scavenger systems, and influencing
prostaglandin levels [29].
1.5 Liver Metastasis of Colorectal Cancer
One of the reasons colorectal cancer is such a pernicious disease is its tendency to
form distant metastases, often in the liver [30]. When nutrients from food are absorbed
from the lumen of the intestines into the bloodstream, the nutrient-rich blood is
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immediately transported from the gastrointestinal tract to the liver via a large vein known
as the hepatic portal vein. This allows the nutrients, as well as any xenobiotics that were
ingested, to be at least partially metabolized before entering systemic circulation. It also,
however, provides a direct transportation route for malignant cells from the intestines to
travel to the liver as well. Additionally, the liver is the body’s primary site of copper
storage, which could potentially contribute to the high frequency of successful metastases
from the intestines that establish in that organ. Epidemiological evidence suggests that
approximately fifteen percent of colorectal cancer patients experience a synchronous liver
metastasis at some point during their lives [31]. Additionally, around twenty percent of
individuals diagnosed with colorectal cancer receive their diagnosis after the primary
tumor has metastasized [32]. Among this group, the five-year survival rate is a bleak
eleven percent, compared to a rate of above eighty-five percent for individuals diagnosed
before a distant metastasis occurs.
In recent decades, a significant body of evidence has emerged that implicates proinflammatory signaling pathways in colorectal tumor metastasis, as well as in
tumorigenesis and progression [32]. Indeed, different types of immune cells, which can
mediate different immune signaling pathways, are alternatively associated with both
tumor-suppressing and tumor-promoting microenvironmental conditions. For example,
several different types of cancers, when highly infiltrated by tumor associated
macrophages (or TAMs), are generally characterized by poor prognosis; however, in
colorectal cancer, tumors that present with elevated levels of T cells are associated with
decreased mortality rates [33]. The most important factor that defines whether a
particular immune cell type is associated with a tumor-suppressing or tumor-promoting
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microenvironment is the cytokines that particular cell type is known to secrete and be
activated by. One particular signaling pathway activated by IL-17 that has been
demonstrated to play an important role in cancer progression is known as nuclear factor
kappa-light-chain-enhancer of activated B cells, or the NF-κB pathway [34]. A protein
complex known to regulate DNA transcription and the production of cytokines, NF-κB
can be activated by a wide array of different ligands, including endogenous cytokines as
well as exogenous molecular patterns associated with invading pathogens. NF-κB
signaling controls the expression of several genes relating to cell survival and
proliferation, and is known to be a response to various harmful stimuli such as free
radicals, cytokines, bacteria, viruses and others [35]. Published literature has specifically
implicated the robust activation of NF-κB signaling in liver metastases of colorectal
cancer as well [36].
1.6 MAPK/ERK Signaling and Cancer
Being a disease characterized by abnormal, uncontrolled cell proliferation, many
different growth pathways play an important role in cancer progression. One of these key
signaling pathways is the MAPK/ERK pathway, named for the mammalian family of
Mitogen-Activated Protein Kinases. Three MAPK families have been well-characterized
in mammalian cells, known as the classical MAPK pathway (also known as the ERK
pathway), C-Jun N-terminal kinase/stress-activated protein kinase (also known as
JNK/SAPK), and p38 kinase. In these cascades, an extracellular signal (hence the ERK
designation – Extracellular-signal Regulated Kinases) binds to a tyrosine kinase receptor
on the surface of the cell, which, in turn, provokes the activation of MAPKs through a
multistep process, made up of no fewer than three enzymes that are activated
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sequentially. These pathways amplify signals from a wide range of stimuli, and are
capable of causing cell growth, proliferation, differentiation, inflammatory responses, and
apoptosis [37].

Figure 1.5 — MAPK/ERK signaling in the pathogenesis of cancer. One of numerous
extracellular signaling molecules first binds to its receptor. A number of downstream
proteins are phosphorylated in a sequential process, eventually leading to the activation
of ERK1/2, JNK1/2, or MAPK14, which then enters the nucleus of the cell and activates
transcription factors or modifies DNA-supporting proteins, thus leading to alteration of
gene expression. Source: Fang, J., & Richardson, B. (2005). The MAPK signalling
pathways and colorectal cancer. Lancel Oncol, 6(5), 322-327.
14

Being involved in stimulating cell growth and proliferation, it should come as no
surprise that dysregulation of the MAPK/ERK pathway has been implicated in many
different types of cancer [37]. Indeed, ERK signaling has been shown to play a
significant role in several events related to tumor development. These include promotion
of cancer cell migration, induced expression of matrix metalloproteins that promote the
degradation of the extracellular matrix, and hence tumor invasion, and regulation of
several proteins involved in apoptosis, which, in turn, promote cancer cell survival [38].
Consequently, the ERK receptor is considered to a robust target for anti-cancer
therapeutic development. Additionally, it has previously been noted that mutations in the
Epidermal Growth Factor Receptor (EGFR), which activates the ERK pathway, have
frequently been observed in colorectal cancers [39].
1.7 Copper Chelation as Anti-Cancer Therapy
As it has now been well-established that copper is crucial for cancer progression,
copper depletion strategies have since become a promising approach for new cancer
therapies. Chelation is defined as when multiple coordinate bonds form between a
polydentate ligand and a central atom, which are almost universally metals [40]. Upon
chelation, the central reactivity of the central atom is reduced, as it is both coordinated
with a ligand and physically separated from the competing ligands that may be capable of
coordinating with the central atom. Before its research application to cancer, copper
chelation therapy had previously been used to treat Wilson’s Disease patients, who
experience systemic copper overload, particularly in the liver and brain. Therefore,
several chelators that were known to be well-tolerated were already in usage, such as
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ammonium tetrathiomolybdate, as well as several others [41]. As mentioned previously,
copper is a critical element required for the process of angiogenesis – the generation of
new blood vessels required for tumor growth and metastasis. Additionally, an emerging
body of evidence suggests that copper can directly promote cancer metastasis as
well. Thus, a number of studies [42] have reported that copper depletion through
chelation therapy is a promising strategy for treating various forms of cancer, and it is
highly likely that research into this direction will continue into the future.
1.8 Inflammation and Cancer
One of the most significant risk factors for developing colorectal cancer, and
many other types of cancers as well, is the presence of chronic inflammation
[32]. Inflammation is an innate immune response against a pathogen, abnormal cell,
injury or chemical irritant characterized by red appearance of the inflamed area, pain,
swelling, and loss of function [43]. The components of inflammation include
vasodilation, increased permeability of blood vessels, invasion of white blood cells into
the affected tissue, as well as a number of complex signaling cascades. The acute
inflammatory response is initiated by immune cells present within the affected area such
as macrophages and dendritic cells, among others. Upon encountering the harmful
stimulus, these cells, which contain pattern recognition receptors, or PRRs, on their
surfaces, bind to the stimulus and are activated, and then begin releasing various proinflammatory mediators. These mediators are in turn responsible for the clinical signs
and symptoms of inflammation and can be broken down into many different categories
such as cytokines, chemokines, enzymes, interferons, and others. The large variety of
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these mediators allows inflammation to fight effectively against a wide range of
pathogens [44].

Figure 1.6 – Immune system signaling and inflammation play a critical role in the risk of
tumorigenesis and cancer progression. Upon recognition of a pathogen by the host’s
immune system via presentation by an APC, a variety of cytokines, both proinflammatory and anti-inflammatory, are released by myeloid cells. These cytokines bind
directly to tumor cells and affect their behaviors relating to cell growth, proliferation, and
invasion, and also regulate the activities of other immune cells, such as regulatory T cells,
TH-1 cells, TH-17 cells, and Natural Killer cells. Critical cytokines that affect tumor cell
behavior include IFNγ, IL-6, IL-10, IL-17, IL-12, IL-23, TNFα, and TGFβ. Source:
Karin, M., Lin, W. (2007). A cytokine-mediated link between innate immunity,
inflammation, and cancer. J Clin Invest, 117(5), 1175-1183.
While the acute inflammatory response has a beneficial defensive effect against
the initiator of the response, chronic inflammation can lead to many negative
consequences in the affected individual. Chronic inflammation can be distinguished from
its acute counterpart not only by the length of the response, but also by the actions of the
17

cells and molecules involved. For example, T lymphocyte infiltration into the affected
tissue is observed in cases of chronic inflammation, but not in the acute response
[43]. The entire pathology of inflammation is remarkably complex, and an exhaustive
description is beyond the scope of this thesis. However, one well known consequence of
chronic inflammation is an increased risk of cancer in the affected tissue. Indeed, over
twenty percent of individuals diagnosed with inflammatory bowel disease will be
diagnosed with colorectal cancer within thirty years of IBD onset, and more than half of
these patients will eventually die from the cancer. Additionally, many colorectal tumors
display increased activity of various pro-inflammatory biochemical pathways, providing
further evidence of the underlying connection between the two conditions [32].
The exact reasons for why chronic colitis increases an individual’s risk of
development of colorectal cancer are not fully understood. However, various
characteristics of inflammation have been implicated in all stages of cancer advancement,
including tumorigenesis, tumor progression and metastasis. One important molecule that
is known to impact inflammation and its effects on cancer is interleukin 17, also known
as IL-17. IL-17 is a pro-inflammatory cytokine produced by helper T cells, known as
Th17 cells, as well as immune sentinel cells, that is known play a critical role in
regulating the innate immune response [45]. Specifically, IL-17 is known to induce IL-6,
IL-8, and several other pro-inflammatory mediators. IL-17 is also known to be a potent
direct activator of neutrophils, as well as several genes that serve anti-microbial
functions. However, this activity also makes IL-17 crucially important in the pathology
of autoimmune disorders, such as psoriasis, rheumatoid arthritis and systemic lupus
erythematosus. This pro-inflammatory activity has also implicated IL-17 in contributing
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to an environment in which tumors can thrive [46]. Interestingly however, and in an
illustration of the “double-edged sword” that is the inflammatory response, where it can
defend a host against foreign threats but can also cause self-damage, some papers have
also reported that IL-17 can protect against cancer growth and metastasis by enhancing
the anti-tumor activity of the immune system [47].
1.9 The Interleukin-17 Signaling Pathway
The existence of IL-17, originally named CTLA8, was first reported in 1993 when
its messenger RNA (mRNA) transcript was isolated from a rodent T cell hybridoma [48].
It was subsequently discovered that the IL-17 family of cytokines consists of several
different molecules, termed IL-17A (often referred to simply as IL-17), IL-17B, IL-17C,
IL-17D, IL-17E (also known as IL-25), and IL-17F. These cytokines are all considered
to be members of the same family because they all exist as homodimers and share five
highly conserved cysteine residues is their C-terminal region that are crucial for the threedimensional structure of the proteins [49], and their genetic coding information is located
in humans on chromosome 6. The IL-17 family of cytokines bind to receptors known,
quite logically, as the IL-17 receptor (IL-17R), which consist of several variants. These
variants are all oligomers, most commonly dimers, which are all comprised of different
combinations of three monomeric subunits, known as IL-17RA, IL-17RB, and IL-17RC
[50]. IL-17A, which shall henceforth be referred to simply as IL-17, consists of 155
amino acid residues and has a molecular weight of 35 kDa [51]. Helper T cells (also
known as CD4+ T cells) that produce IL-17 are known as TH-17 cells. Naïve T cells can
be differentiated into a TH-17 lineage upon stimulation with several different ligands,
including transforming growth factor beta (TGF- β), IL-6, and IL-23 [52]. Like other
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CD4+ cells, TH-17 cells are activated after an antigen presenting cell (APC), such as a
macrophage, ingests an invading pathogen and presents a fragment of a peptide from that
antigen on a specialized surface protein, known as a class 2 major histocompatibility
complex (MHC). The antigenic peptide fragment bound to the class 2 MHC on the
surface of the APC then binds to the CD4 protein on the surface of the helper T cell, thus
activating the T cell and causing it to begin releasing its signature cytokine [53]. In the
case of TH-17 cells, this signature cytokine is, unsurprisingly, IL-17, though TH-17 cells
also produce and secrete IL-22 [54].

Figure 1.7 – IL-17 increases expression of many genes through activation of various
downstream signaling pathways. IL-17A, commonly referred to as IL-17 without
qualification, exists as a heterodimer. IL-17 binds to the IL-17 receptor complex, referred
to as IL-17R, forms a homodimer consisting of one IL-17RA subunit and one IL-17RC
subunit upon ligand binding. Both subunits of IL-17R possess a SEFIR domain, which
recruits Act1 upon activation of the receptor complex. Act1 can then bind to TRAF6, and
also acts as an E3 ligase that ubiquitinates TRAF6. TRAF6, in turn, acts as an E3 ligase
and ubiquitinates TAK1, which can then directly activate the NF-κB pathway. The Act1TRAF6-TAK1 pathway can also activate the MAPK/ERK and C/EBP signaling
pathways. IL-17R can also activate the PI3K/JAK pathway through a yet unknown
mechanism. Additionally, TRAF3 can act as a negative regulator of IL-17R activity.
Additionally, activated IL-17R can also form an Act1–IKKi–TRAF2–TRAF5–SF2(ASF)
20

complex that promotes mRNA stability and increases expressions of genes induced by
IL-17. Source: Source: Zhu, S., Qian, Y. (2012). IL-17/IL-17 receptor system in
autoimmune disease: mechanisms and therapeutic potential. Clin Sci, 122(11), 487-511.
IL-17 signaling plays many important roles in immune system function,
particularly those related to host defense against bacteria and fungi. IL-17R is found
abundantly on various types of cells in mucosal barriers, such as epithelial cells and
fibroblasts [55]. These mucosal barriers line areas of the body that are exposed to the
outside world, such as the skin, gastrointestinal tract, nasal cavity, urinary tract, and
reproductive tract, as well as others. Upon stimulation of IL-17R by a ligand, the target
cell begins producing antimicrobial peptides, such as β-defensins, S100 proteins, and
regenerating islet-derived protein 3g (ReG3g), which function as endogenous antibiotics
through mechanisms such as disrupting prokaryotic membranes and interfering with the
function of critical bacterial cellular processes [56]. The other main function of IL-17
signaling involves sustaining a pro-inflammatory response. IL-17 stimulation of cell has
been reported to increase expression of other pro-inflammatory cytokines, such as IL-1β,
IL-6, GM-CSF, G-CSF and TNFα from many types of cells, including fibroblasts,
macrophages, chondrocytes and osteocytes [57]. IL-17 additionally stimulates increased
expression of many chemokines which recruit leukocytes to the stimulated tissue. These
include CCL2, CCL7, CXCL1, CXCL2, CXCL5 and CXCL8, which recruit neutrophils
and monocytes from the bloodstream, CCL20, which recruits additional IL-17-producing
immune cells, and CXCL9 and CXCL10, which further recruit leukocytes to the affected
tissue. An additional way that IL-17 promotes recruitment of immune cells to the target
tissue is through promotion of vasodilation and activation of tissue remodeling genes.
Cells stimulated with IL-17 may undergo structural changes in their extracellular
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matrices through modification of the expression of several different matrix
metalloproteinases. Through these various mechanisms, IL-17 sustains a proinflammatory environment [57].

Figure 1.8 — IL-17 and the pathogenesis of cancer. Upon stimulation by a pathogen, one
of many different immune cells, including Paneth cells found in the epithelium of the
small intestine, begins secreting IL-17. This has a number of tumor-promoting effects,
including stimulating the release of other cytokines from target cells, inhibition of
cytotoxic T cells, and promotion of tumor-initiating cells and tumor vessels. Source: Wu,
D. (2013). Interleukin-17: A promoter in colorectal cancer progression. Clin Dev
Immunol.
However, this type of positive feedback response has a significant drawback –
namely, that sustained activation of IL-17 signaling has been implicated in many
different autoimmune disorders. Autoimmune diseases are a broad class of disorders
characterized by an immune response by a host against the body’s own cells and tissues.
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Common autoimmune disorders include Systemic Lupus Erythematosus (SLE),
Rheumatoid Arthritis (RA), Type 1 Diabetes Mellitus, Multiple Sclerosis (MS), and,
most relevant to this thesis, Inflammatory Bowel Disease (IBD). While the pathogeneses
of these diseases are not fully understood, it is believed that IBD is caused by an
abnormal immune response against the gastrointestinal microbiota. Previous reports have
shown that IL-17 expression is increased in the mucosa of the large intestine as well as
the serum of IBD patients compared to normal patients [58]. Further studies have
confirmed through animal models that IL-17 signaling plays a crucial role in the
pathogenesis of IBD [59]. However, given the current body of evidence relating IL-17
and IBD, it is still unclear whether the cytokine has disease-promoting effects or
protective effects against the disease, or both, as it has been shown that both animal
models of IBD in which IL-17 production was decreased or knocked out entirely, and
human patients treated with anti-IL-17 drugs, displayed exacerbated symptoms, rather
than relief from them [60].
1.10 Animal Modelling of Colon Inflammation and Cancer
Many animal models of colitis and colorectal cancer have been developed by
researchers seeking to study these diseases. These models can be characterized according
to several variables, such as the method by which the disease is introduced to the animal,
and whether a cancer model is likely to metastasize. One category encompasses models
in which the animals are genetically modified to spontaneously develop tumors. For
example, mouse models of colorectal cancer can be created by generating specific
mutations, such as those that affect the WNT signaling pathway, or DNA mismatch
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repair proteins. Various other genes that may be modified include p53, KRAS, SMAD3,
and others that are frequently mutated in clinical cases of colorectal cancer [61].

Figure 1.9 – Molecular structures of dextran sodium sulfate (DSS) and azoxymethane
(AOM). AOM reliably induces colon carcinoma after intraperitoneal (IP) injection. It is
therefore often used for this purpose in animal model experiments. It is believed that the
mechanism of AOM-induced carcinoma involves inducing DNA base pair mismatches or
disrupting normal mismatch repair mechanisms. Similarly, DSS reliably induces colon
inflammation when delivered as an aqueous drinking water solution, and is often used in
animal model experiments for this purpose. It is believed that DSS achieves this by acting
as detergent that disrupts the normal mucosal lining of the colon, allowing gut flora to
penetrate into the submucosal and muscular layers of the colon, thus generating an
immune response. Source (DSS): Tanaka, T. (2011). Development of an InflammationAssociated Colorectal Cancer Model and Its Application for Research on Carcinogenesis
and Chemoprevention. Int J Inflam, 2012. Source (AOM): Wikimedia Commons.
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Another broad category of colorectal cancer animal models are those that are
chemically induced. The most commonly used colon inflammation model is the dextran
sodium sulfate, or DSS model, in which the animal’s drinking water is replaced with a
dextran sulfate sodium solution, for either one or multiple cycles, punctuated by
“recovery” cycles of unaltered drinking water. While the exact mechanism by which
DSS administration induces colitis is not fully understood, it is believed that the chemical
degrades the mucosal barrier of the large intestine by acting as a detergent, leading to
infiltration of gut bacteria into the lining of the colon, which provoke an immune
response [62]. Other colon inflammation models used include rectal administration of
2,4,6-trinitrobenzenesulfonic acid, or oxazolone dissolved in ethanol (which is required
to penetrate the mucosal barrier.) While some animals that experience intestinal
inflammation do spontaneously develop tumors at an increased rate, these models are
typically combined with a one-time administration of azoxymethane (AOM), which
reliably induces colorectal adenocarcinomas, most likely by causing the mismatching of
nucleotide base pairs during DNA replication [63].
1.11 Engineering Recombinant Cell Lines and Proteins
For well over a century now, cells grown in vitro, or outside of the organism from
the cells were derived, have been an invaluable tool for biological research. While whole
organs isolated from animals were maintained in media containing ions and molecules
necessary for life in the 19th century, research in cell culture took major steps forward in
the mid-20th century, which allowed cell monolayers to be grown, for which the 1954
Nobel Prize in Medicine was awarded [64]. In modern times, a large assortment of
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different cell growth media exists, capable of sustaining virtually any type of cell
imaginable.
For certain experiments, in which a researcher is interested in investigating the
function of a particular protein, the gene corresponding to that protein may be
overexpressed, knocked out, or knocked down in a cell line. Due to the nature of the
experiments detailed in this thesis, overexpressed cell lines shall be described. The
introduction of purified, or “naked” DNA into a eukaryotic cell is known as a
transfection. This is in contrast with performing the same action on a prokaryotic cell,
which is typically called a translation. Expression of a gene may be induced either
stably, where the foreign nucleic acid is integrated into the nuclear DNA of the
transfected cell, or transiently, in which the transfected DNA remains in the cytosol.
After purification of the DNA, there are several methods which may be used to transport
the DNA across the cellular membrane. These methods may be classified as biological,
chemical, or physical in nature, and include techniques such as using a viral vector, use of
calcium phosphate, a cationic lipid or polymer vector, electroporation, sonoporation, laser
irradiation, or use of magnetic nanoparticles [65]. Biological methods, such as
introduction of DNA using a viral vector, are efficient and commonly used for
experiments in which stable gene expression is desired, as they take advantage of the
natural ability of viruses to integrate their genetic material into the genome of a host.
They carry the significant downside, however, of potentially evoking an immune
response from the host cell. Chemical methods take advantage of positively charged
vectors, such as cationic lipids or cationic polymers, which are attracted to the negatively
charged lipid bilayer of the cell. While the exact mechanism by which the nucleic acids
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pass through the cell membrane is not fully understood, it is believed to be endocytotic or
phagocytotic in nature. While these chemical methods do not carry the risk of generating
an immune response, they are considerably less efficient than viral vectors and may
damage the cells. Finally, physical methods, such as sonoporation, laser-based
transfection, and electroporation, utilize these tools to generate holes in the cell
membranes which allow the nucleic acids to travel through. Similarly to chemical
methods, physical methods do not evoke an immune response in the host cells, but are
less efficient than biological methods and may damage the cell.
After the purified DNA is transported into the host cell, if it is transiently
expressed, target gene expression will decrease exponentially in each subsequent
generation due to dilution of the genetic material in daughter cells following mitosis, and
is typically only observable for several days [66]. Thus, for most experiments in which
overexpression of a gene is to be investigated, a stable transfection is required. In
addition to the gene of interest, a “marker” gene must be co-transfected into the cell as
well, typically one that confers resistance to an extracellular toxin. This allows the
researcher to specifically select for clones of cells that have integrated the foreign DNA,
consisting of the both gene of interest and the marker gene, into their genome, as only
clones of cells which have done so will survive in culture after addition into the medium
of the toxin to which the stably transfected cells are now resistant due to expression of the
marker gene. Additionally, a target gene may be modified, or “tagged”, by addition of a
nucleotide sequence to the complementary DNA (cDNA) of the gene that is to be
expressed, which causes the gene to manufacture that specific amino acid sequence in
addition to its normal amino acid sequence during protein construction. Tags allow for
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use of antibodies that bind to that specific amino acid sequence within the recombinant
gene, which allows a researcher to purify the desired protein by an affinity technique, as
well as to quantify expression level of the protein it by Western blotting. Commonly
used protein tags include the polyhistidine tag, the FLAG tag, the glutathione stransferase tag, as well as others [67].
Further, to eliminate the complicating variables of how modifying the genome of
a cell line may affect its normal behavior compared to the unmodified cells, “inducible”
cell lines are often generated. One common mechanism by which this is accomplished is
through the tetracycline-controlled transcriptional activation method, which allows a
researcher to either provoke (termed “Tet on”) or block (termed “Tet off”) expression of
the gene of interest in the cells via addition of the antibiotic tetracycline, or a derivative
antibiotic, such as doxycycline, to the growth medium [68]. These tetracycline-inducible
systems make use of a recombinant protein generated from the tetracycline repressor
protein, originally discovered in E. coli, which prevents expression of tetracycline
resistance-related genes when bound to its operator, fused with a fragment of another
protein known as a transactivation domain, which provides scaffolding that allows RNA
polymerase to bind to the promoter region of the DNA, and thus initiate transcription of
the genes controlled by the promoter. In the case of a Tet on system, the tetracyclinebinding domain of this recombinant protein binds to a tetracycline molecule, thus
changing the conformation of the protein in such a way that allows it to bind to its
operator [68]. After the recombinant protein has bound to its operator segment of DNA,
the transactivation domain of the recombinant protein then enables RNA polymerase to
bind to the promoter region of the DNA, which in turn leads to expression of the gene or
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genes controlled by that promoter. The operator, promoter, and genes controlled by those
segments of DNA are collectively referred to as an operon. Similarly, in the case of the
Tet off system, the tetracycline-binding region of the fused protein is mutated such that
tetracycline binding changes its conformation in a way that causes it to detach from its
operator, thus preventing the binding of RNA polymerase to the promoter, mediated by
the transactivation domain of the recombinant protein, and subsequent expression of the
genes within the operon [68]. These types of systems have been in use for many years,
and it has been demonstrated that these systems can be used to generate stably
transfected, inducible human cell lines [69]. However, the use of tetracycline-inducible
cell systems does carry the risk of altering cell metabolic processes and proliferation
through exposure to doxycycline [67].
1.12 Determination of Metal Content in Solution by AAS
An effective method of determining the concentration of metals in a solution is
atomic absorption spectroscopy, also known as AAS. In use since the 1950s, AAS
instruments follow the general procedure of forcing the sample into the gas phase and
atomizing it with some form of heat energy, then passing light of a wavelength specific to
the element being determined through the atomized sample, and then measuring how
much of the light is absorbed by the sample, which corresponds directly to the
concentration of that element in the solution [70]. Two common methods of sample
heating and atomization are by aspirating the sample into a flame, known as flame atomic
absorption spectroscopy (FAAS), and alternatively by heating the sample in a small
furnace made of graphite, which is known as graphite furnace atomic absorption
spectroscopy (GFAAS).
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CHAPTER II
EXPERIMENTAL AIMS AND PROTOCOLS
2.1 Project Rationale and Overall Hypothesis
In 2015, unpublished data from the Li Lab, seeking to identify genes whose
expression in keratinocytes was upregulated after three hours of stimulation with IL-17,
was generated from a quantitative proteomic analysis. This analysis revealed a that a of
significant number upregulated genes were copper-related — most notably, STEAP4.
From this data, it was hypothesized that the mechanism by which IL-17 signaling sustains
a pro-inflammatory, tumor-promoting response may be dependent upon copper
metabolism, and STEAP4 activity specifically. Prior to the generation of this data, no
copper or STEAP4-dependent mechanism had ever been described in the published
literature.
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Table 2.1 – Many copper-related genes are upregulated in epithelial cells stimulated with
IL-17. STEAP4 functions as a copper reductase and ceruloplasmin (Cp) is the primary
carrier of extracellular copper in the body. Lysyl oxidase (LOX) proteins are a class of
copper-dependent enzymes that catalyze formation of crosslinks within various types of
connective tissues. Source: Li Lab, Department of Immunology, Lerner Research
Institute, Cleveland Clinic Foundation.

Thus, the Li Lab sought to investigate a potential copper-dependent mechanism,
mediated by STEAP4, that promoted the pro-inflammatory activity of IL-17. Thus, the
aims of the experiments presented in this thesis can be described thusly:
Aim 1: Determine whether STEAP4 overexpression and IL-17-signaling promotes
copper uptake by colon epithelial cells, and whether induction of inflammation mobilizes
copper from latent storage into systemic circulation.
Aim 2: Identify a biochemical mechanism by which IL-17-mediated copper uptake
promotes growth in colon epithelial cells.
Aim 3: Determine whether systemic chelation of copper mitigates tumorigenesis in a
mouse model of inflammation-associated colorectal cancer.
It was determined that Aim 1 would be investigated through several cell-based
experiments. The first experiments would investigate whether STEAP4 overexpression
of a colon cancer cell line increased uptake of extracellular copper by the cells compared
to cells in which STEAP4 was expressed normally. An additional experiment would seek
to determine whether IL-17 stimulation of colon cancer epithelial cells took up more
extracellular copper than colon cancer cells which were not stimulated with IL-17.
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Finally, a third experiment utilizing a mouse model of colon inflammation would be
performed in which animals would be sacrificed throughout the course of the experiment,
and the concentration of copper in the liver and the serum would be measured through an
atomic absorption method. Aim 2 would be investigated by conducting another cellbased experiment in which activation of growth-promoting signaling pathways would be
quantified by Western blot, and this activation would be compared between cells in
which STEAP4 was overexpressed and STEAP4 was expressed normally. Finally, Aim 3
would be investigated by utilizing a mouse model of inflammation-associated colorectal
cancer, and comparing the number of colon tumors that developed in animals whose body
copper levels were left unaltered to animals whose body copper levels were depleted
through the administration of a copper chelator by oral gavage.
2.2 Cell Culture
The human colon carcinoma cell line known as LS147T, obtained from the
American Type Culture Collection, was used for all cell-based experiments. Cells were
grown in high glucose Dulbecco’s Modified Eagle Medium, which was supplemented
with 10% fetal bovine serum and 2% penicillin-streptomycin. Cell culture dishes were
kept in incubators maintained at 37 °C, containing 95% air and 5% CO2. Prior to
harvesting, all cell handling techniques were performed in class 1 biological safety hoods.
2.3 Engineering FLAG-Tagged STEAP4-Inducible LS147T Cells
The STEAP4-inducible cell line was generated by cloning a C-terminal FLAGtagged STEAP4 cDNA sequence into the pLIX_403 vector. 3 μg of the expression
vector was then transfected into HEK-293FT cells using the Lipfectamine2000 reagent,
purchased from ThermoFischer, according to the manufacturer’s instructions. Medium
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from these cells, containing Lentivirus, was then harvested and filtered with 0.45-μM
Millex-HP filter 36 hours after the transfection was performed. LS147T cells were then
transfected with the Lentivirus using a 1:1 ratio of fresh medium and filter medium
containing Lentivirus for 24 hours. Following this, cells were then cultured in fresh
medium for 72 hours, and then transfected cells were selected for by growth in medium
containing 1 μg/ml puromycin for one week. Finally, cell clones were harvested, and
expression of FLAG-tagged STEAP4 was confirmed by Western blot.
2.4 Treatment and Harvesting of Cultured Cells
Before being used in any experiments, cultured cells were grown to around 50%
confluence. In the experiments in which the STEAP4-inducible cell line was used, cells
receiving doxycycline were treated with 200 ng/mL of the antibiotic 24 hours before any
cytokines or copper supplements were added to the medium. Cells used in the copper
determination experiments were grown in cell culture dishes with a diameter of 60 mm,
and cells used in the cell signaling experiments in which copper was not determined were
grown in dishes with a diameter of 35 mm.
In the experiments in which intracellular copper content was measured by atomic
absorption spectroscopy, a bulk 100 mM copper sulfate (CuSO4) was prepared with fresh
Milli-Q water and was then autoclaved to ensure sterility. Cells treated with copper
received the CuSO4 solution by micropipetting such that the final concentration of copper
in the medium was 50 μM, not including any copper originally contained therein, at the
zero timepoint of the experiment. If cells were treated with both copper and cytokines,
the cytokine treatment (50 ng cytokine/mL medium) was administered 24 hours before
the copper supplement was added to the medium. The time of copper administration was
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defined as the zero timepoint of the experiment. After addition of copper solution or
cytokines to the cell medium, the culture dishes were gently swirled for several seconds
to distribute the supplements evenly throughout the medium. In the cell signaling
experiments not involving copper measurements, cells were treated with cytokine at the
zero timepoint, and were then harvested at the timepoints specified in the figures.
Upon harvesting the cells, the medium was removed from the cell dishes by
vacuum aspiration. If copper was administered during the experiment, cells were rinsed
once with ice cold phosphate buffered saline (PBS) containing 0.1 M
ethylenediaminetetraacetic acid (EDTA) to ensure that all extracellular copper was
removed, and then once with unaltered, ice cold PBS. If copper was not administered,
cells were rinsed twice with unaltered, ice cold PBS. After rinsing, cells were then lifted
from the dish with a cell scraper, which was rinsed with PBS and dried with a paper
towel in between each use, and then were suspended in PBS. The cell suspension was
then transferred to a 15-mL plastic centrifuge tube by pipette. Before centrifugation, the
cell suspensions were kept on ice. Cells were then centrifuged for 5 minutes at 3,000
RPM. Following centrifugation, the supernatant was then removed by vacuum
aspiration.
In the experiments in which copper was to be determined, cells were lysed using
300 mL of aqueous lysis buffer containing 0.5% Triton X-100, 20 mM HEPES, 150 mM
NaCl, 12.5 mM β-glycerophosphate, 1.5mM MgCl2, 10 mM sodium fluoride (NaF), 2
mM dithiothreitol, 1 mM sodium orthovanadate, 2 mM ethylenebis(oxyethylenenitrilo)tetraacetic acid (EGTA), 20 mM aprotinin and 1 mM
phenylmethylsulfonyl fluoride, prepared in Milli-Q water, where the pH was adjusted to
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between 7.4 and 7.6. The total protein contents of the raw lysates were then measured by
ultraviolet-visible spectrophotometry, using the Bradford protein assay (595 nm), so that
the copper content of the samples could be adjusted based on the quantity of cells in each
sample. This was accomplished by adding 10 μL of lysate to 1 mL of Bio-Rad Protein
Assay Dye Reagent (diluted 5x in Milli-Q water) into a 1-mL cuvette with a pathlength
of 1 cm and then pipetting up and down for several seconds to mix the solution. A
standard curve was generated using bovine serum albumin (BSA) protein solutions of
known concentrations. If any samples registered an absorbance value outside the range
of the standard curve, the samples were discarded, and the assay was repeated for all
samples by adding a smaller volume of lysate into 1 mL of the protein assay reagent dye
until all values were within the range of the curve. After determination of the protein
concentrations, 0.7 mL of concentrated nitric acid, purchased from Sigma-Aldrich, were
added to the samples (in 1.5-mL microcentrifuge tubes), which were then briefly
vortexed and allowed to sit in a 37 °C incubator for 30 minutes to an hour. Samples were
then analyzed by atomic absorption spectroscopy (detailed below) after being diluted 10fold by pipetting 100 μL of acid/lysate homogenate into a fresh 1.5-mL tube containing
900 μL nitric acid. Samples that were not immediately analyzed by AAS were placed in 80 °C storage until the time of analysis.
In the experiments in which intracellular protein contents were to be determined
by Western blot, cells were lysed using the same lysis buffer described above. Protein
concentrations in each sample were determined by ultraviolet-visible spectroscopy using
the method described above, without generating a standard curve. To normalize the
protein content of each sample, the most protein-dilute sample was left unaltered, while
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all other samples were diluted with lysis buffer based on the ratio of the absorbance T
595 nm of the sample in question to the absorbance at 595 nm of the most dilute sample,
such that the final volume of each sample was 1 mL. After the total protein
concentrations of the samples were adjusted, each one was mixed with 2x Laemelli
sample buffer, supplemented with 100 μL of 2-mercaptoethanol per 900 μL of sample
buffer. Samples were then boiled for 5 minutes at 95 °C and kept in -20 °C storage until
the time of analysis by Western blot.
2.5 Quantitative Analysis of Proteins by Western Blot
All samples analyzed by Western blot were separated on 10% SDS-PAGE gels
prepared using National Diagnostics reagents, which were run at 100 V. The running
buffer was a deionized water solution containing 2 M glycine, 0.25 M Tris-HCl, and 0.02
M sodium dodecyl sulfate (SDS). After running the separation gel, protein bands were
transferred to a poly(vinylidene difluoride) (or PVDF) membrane pre-soaked in 95%
methanol. Each transfer was run for 2 hours at 80 V where the box containing the gel
and membrane were kept in an ice bath. The transfer buffer was prepared in deionized
water and contained 25 mM Tris-HCl, 200 mM glycine, and 10% methanol. After the
transfer, the membrane was blocked with 5% milk solution, dissolved in a wash buffer
prepared using deionized water, containing 50 mM Tris-HCl, 150 mM NaCl, and 0.1%
Tween-20. After blocking, the membrane was incubated at 4 °C overnight, with gentle
shaking, in a primary antibody solution, dissolved in 5% BSA solution prepared in wash
buffer. The membrane was then rinsed five times, for five minutes each, in wash buffer,
with gentle shaking. Following this, the membranes were then incubated for one hour in
the corresponding secondary antibody solution, dissolved in a 5% milk solution prepared
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in wash buffer. The membrane was then rinsed again five times, for five minutes each,
using wash buffer and gentle shaking. Finally, the membrane was then placed on plastic
wrap and then soaked in chemiluminescent Western blot detection reagents obtained
from Thermo Fisher for approximately 30 seconds, and then placed in a cassette with
autoradiography films and images were obtained using a film developer. The intensity of
the protein bands was quantified using ImageJ image processing software.
2.6 Animal Modelling of Colitis and Cancer
Mice were maintained in the Biological Resources Units at Lerner Research
Institute of the Cleveland Clinic Foundation. In experiments modelling inflammation
only, drinking water in each cage was replaced with an aqueous, 3% dextran sodium
sulfate solution for the duration of the experiment to induce colitis [71]. Mice were fed
with standard chow and ear tags were used to identify each animal. In mice where both
inflammation and colon cancer were modelled, this was achieved by a one-time
intraperitoneal injection of azoxymethane (AOM), using 15 mg of the substance per kg of
body weight, followed by 3 cycles where drinking water was replaced with a 1.5% DSS
solution for 5 days, with two weeks of unaltered drinking water in between each cycle.
The first 5-day cycle of DSS solution began on the day of AOM administration. Mice
given ammonium tetrathiomolybdate (TTM) were administered treatment of aqueous
TTM, using 20 mg per kilogram of body weight, once every three days by oral gavage.
2.7 Animal Sacrifice and Sample Collection
At the time of sacrifice of inflammation-only animals, mice were transported from
the BRU to the Li Lab and were administered a 200 μL dose of ketamine through
intraperitoneal injection. Immediately after unconsciousness was induced, but while the
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animal was still alive, the abdomen was opened with a Y-shaped cut performed with
surgical scissors, and a blood sample was collected by cardiac puncture using a 19 G
needle attached to a 1-mL syringe. As much blood was collected as possible and was
placed in a 1.5-mL microcentrifuge tube after collection. Blood samples were placed on
ice immediately after collection and were then centrifuged at 4° C for 15 minutes at 1,000
RPM for 15 minutes. 100 μL of serum was then removed from the microcentrifuge tube
by micropipette and was placed in a fresh 1.5-mL tube. The serum was then stored in a 80° C freezer until the time of analysis. Immediately prior to copper analysis, 900 μL of
concentrated nitric acid was added to the tube, which was briefly vortexed and then
allowed sit in a 37 °C incubator for 30 minutes to 1 hour. After blood collection, a sample
of the animal’s liver then was removed and placed in a 1.5-mL plastic microcentrifuge
tube, which was then placed on dry ice, and later into storage in a -80° C freezer.
Immediately before copper analysis, the liver samples were digested in 15-mL centrifuge
tubes containing 1 mL concentrated HNO3 for 30 minutes to 1 hour in a 37 °C incubator.
After then being briefly vortexed, 100 μL of liver homogenate was then pipetted into a
fresh 1.5-mL microcentrifuge tube containing 900 μL nitric acid to generate the sample
that would be tested for copper by atomic absorption.
At the time of sacrifice of colitis-associated carcinoma mice, which was at the
conclusion of the third cycle of unaltered drinking water, 8 weeks after AOM injection,
animals were brought back to the Li Lab from the BRU and sacrificed by CO2
asphyxiation. After sacrifice, the abdomen of the animal was opened with a Y-shaped cut
and the colon was carefully removed and placed in a dish containing PBS. The colon
was then carefully opened longitudinally with scissors and any feces were removed by a
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gentle wiping with a PBS-soaked paper towel. Tumor nodules, which were defined as
lesions on the colon measuring 1 mm in diameter or greater, were counted visually.
2.8 Determination of Copper by Atomic Absorption

Figure 2.1 — Overview of an atomic absorption spectrometer. A light beam of a specific
wavelength is passed through the atomized sample, where the transmittance is compared
to the intensity of a reference beam. The wavelength used is specific to the element
being analyzed. Source: http://lab-training.com/wp-content/uploads/2013/03/DoubleBeam-AAS-Schematic-Diagram.png
All experiments were performed using a Varian FS220 atomic absorption
spectrometer from the Case Western Reserve University Department of Chemistry.
Samples were analyzed in triplicate using a graphite furnace method. The wavelength
used was 324.8 nm with a slit width of 0.5 nm. The following stages of heating were
used in the method:
Stage number
Temperature (°C)
Time (s)
1
85
5
2
95
40
3
120
10
4
800
5
5
800
1
6
800
2
7
2300
0
8
2300
2
9
2300
2
Table 2.2 — Stages of heating used in the AAS method. The first three stages are the
drying stages, in which water and other volatile solvents present in the solvent are boiled
off. Stages four through six are the ashing stages, in which other organic molecules of a
higher boiling point are removed from the sample. The final three stages are the analysis
stages, in which the element to be analyzed is atomized and analyzed, and then the
furnace is heated again to remove any remaining analyte.
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Samples were kept under nitrogen gas during analysis and a flow rate of 3 L/min
was used. No matrix modifiers were used. The calibration curve was generated using the
“automix” feature of the instrument, where the bulk material for standards was a 500
μg/L solution of CuSO4 prepared in concentrated HNO3, and the makeup material was
unaltered concentrated HNO3.
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CHAPTER III
RESUTLS AND DISCUSSION
3.1 STEAP4 Overexpression Increases Copper Uptake by Colon Cancer Cells
A

B

C

Figure 3.1 — Copper uptake by STEAP4-inducible LS147T cells. Cells were grown to
around 50% confluence in 60-mm diameter dishes at the time of doxycycline treatment.
A) The change in intracellular copper concentrations over 4 hours in cells treated with
doxycycline versus untreated cells. p = 0.04. B) intracellular copper concentration
measurements at each timepoint in treated and untreated cells. C) Expression of FLAGtagged STEAP4 in doxycycline-treated cells and untreated cells. All copper
measurements were done by GFAAS and each data point was analyzed in triplicate. Error
bars represent the standard deviation of each data point.
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It has been previously reported [5] that overexpression of STEAP4 in increases
the hourly rate of environmental copper uptake in HEK-293T cells, a line derived from
human embryonic kidney cells, by approximately 20 percent. And indeed, the data
shown in Figure 3.1 indicates from the time of copper treatment (defined as “0 hr”) until
4 hours after treatment, STEAP4-overexpressed colon cancer cells take up more
extracellular copper from their environment than cells in which STEAP4 is expressed
normally. Further, the difference of around 20 percent in the average hourly rates of
copper uptake in STEAP4-overexpressed cells compared to cells in which STEAP4 is
normally expressed agrees quite well with what has been previously reported. While
copper is an essential trace nutrient required by all living systems, it is also true that
excess intracellular copper can cause a variety of deleterious biological effects through a
chemistry known as the Fenton reaction [72], which occurs via the following scheme:
Cu+ + H2O2 → Cu2+ + HO• + OH−
This immune-mediated production of free radical-containing reactive oxygen
species (ROS) through using copper as a redox partner can be used by an organism for
host defense purposes, as macrophages are known to release unbound copper ions upon
encountering an invading pathogen in a process known as the “respiratory burst” [73].
The primary defensive benefit of this procedure is to cause oxidative damage to a variety
of cellular components of the pathogen, particularly its lipids and DNA. For this reason,
when stored physiologically, copper must be kept bound to one of many coppercoordinating proteins. Thus, while little data exists to date exploring the potential
connection between dietary copper intake and the likelihood of developing various types
of cancer – and in fact, surprisingly little is known about the typical amount of copper
42

consumed by humans who eat modern Western diets, or even the optimum daily intake of
the nutrient for adults [11] – it is reasonable to speculate that a higher than normal
concentration of body copper, which is partially dependent on STEAP4 expression, may
cause an increased risk of tumorigenesis, perhaps due to increased oxidative damage to
DNA and subsequent deleterious mutations that copper-mediated Fenton chemistry can
cause. It may also be speculated that high body copper levels could potentially lead to
increased rate of cancer progression after a tumor has already been established, as copper
is required for cell growth generally, as well for angiogenesis [74], the process of creating
new blood vessels which provide required nutrients to a growing tumor. Further
supporting this idea are previous studies which have reported increased intracellular
copper concentrations in a variety of cancers, including colorectal cancer [75]. The full
extent of the time scale over which STEAP4 expression affects intracellular copper levels
remains unclear, however. Additional investigation into this question is suggested to gain
a clearer picture of this connection.
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3.2 IL-17 Stimulation Increases Copper Uptake by Colon Cancer Cells
A

B

Figure 3.2 — Copper uptake by IL-17-treated and untreated LS147T cells. All samples
were analyzed in triplicate by GFAAS. A) The change in intracellular copper
concentrations from over 4 hours in cells treated with IL-17 versus untreated cells. p =
0.01. B) Intracellular copper concentration measurements at each timepoint in cytokinetreated and untreated cells. All copper measurements were done by GFAAS and each
data point was analyzed in triplicate. Error bars represent the standard deviation of each
data point.
Previously published data from the Li Lab has shown that IL-17 stimulation
upregulates the expression of STEAP4 in keratinocytes [76]. Further, it has long been
known that copper plays a critical role in the regulation of the inflammatory process [77],
though the mechanism of this regulation is still not fully understood, outside of the
copper-involved respiratory burst mediated by neutrophils, monocytes, and other immune
cells. It has also long been known that IL-17 signaling is a critical factor in the
progression of colorectal cancer, due to its previously reported pro-inflammatory effects
and promotion of a tumor-friendly microenvironment [78]. Previous experiments with
inflammation-associated colorectal cancer mice, induced through DSS-AOM treatment,
have found that deletion of the IL-17A receptor partially protects against development of
colorectal cancer in a genetically-modified mouse model [79]. However, the mechanisms
of IL-17’s promotion of cancer progression are not yet fully understood. It has been
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proposed that these mechanisms may include suppression of the anti-tumor immune
response mediated by cytotoxic T cells, promotion of angiogenesis, and activation of the
JAK/STAT signaling cascade, which has previously been implicated in the pathogenesis
of several different types of cancer [80]. To date, however, the mechanism of IL-17’s
promotion of tumorigenesis and tumor progression has not been linked directly to a
copper-mediated mechanism in the literature. Data presented in this thesis suggest that
this previously proposed promotion of angiogenesis by IL-17 may be driven by its
upregulation of STEAP4, and the resulting increase in the copper levels of tumor cells.
Though IL-17-producing CD4+ T cells (also known as Th17 cells) were
originally thought of as the only significant producers of IL-17, evidence has since
emerged that many different types of immune cells are capable of producing the cytokine
as well, particularly innate immune cells such as natural killer (NK) cells and neutrophils
[81]. Interestingly, it has also been reported that a highly specialized type of epithelial
cell found in the intestinal crypts known as Paneth cells are capable of rapidly producing
IL-17 (and other pro-inflammatory mediators) upon exposure to inflammatory cytokine
signals [82]. Enterocytes, the epithelial cells that line the lumen of the small intestine, are
the primary cells responsible for the uptake of dietary copper, after its reduction from the
cupric state to the cuprous state [83]. Thus, taking the data from Figure 3.2 into account,
it can be reasonably inferred that the presence of inflammation in the gut, which directly
causes the sustained release of IL-17 by Paneth cells, likely stimulates increased uptake
of dietary copper in vivo, and thus creates a positive feedback loop which sustains the
local inflammatory response, thereby creating a tumor-promoting microenvironment.
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One additional implication of the crucial role that copper metabolism plays in the
progression of cancer is its relevance to platinum-containing anti-cancer drugs. A
mainstay of frontline treatments for many types of cancer, including colorectal cancer,
platinum therapies such as cisplatin (often referred to as the “penicillin of cancer”), as
well as oxaliplatin, commonly prescribed to colorectal cancer patients, are known to
cause cell death by mediating DNA damage through a mechanism of generating both
intrastrand and interstrand crosslinking via platinum adducts, which in turn induces
apoptosis [84]. As these platinum-containing drugs are taken up into the cells by copper
transport proteins including ATP7A, ATP7B, and most notably CTR1, they affect rapidly
dividing cells most strongly, and thus can effectively target malignant cells while
minimizing damage to healthy tissues [85]. However, with the exception of germ cell
tumors, acquired resistance to these drugs is a virtually unavoidable result of platinum
therapy [86]. It is possible that treatment with copper chelators may be able to mitigate
this problem, however, as it has been reported that the uptake of platinum-based drugs by
tumor cells can be enhanced through treatment with ammonium tetrathiomolybdate [87].
While further study into this route of treatment is required to better elucidate its
effectiveness, it is suggested that copper chelation by TTM may incur the dual benefits of
reducing the tumor-promoting effects of copper uptake via promotion of angiogenesis
and stimulation of cell growth and proliferation, and also by re-sensitizing tumor cells to
DNA damage caused by platinum therapy, by upregulating the expression of copper
uptake membrane proteins such as CTR1 that are responsible for platinum uptake into the
cell.
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3.3 Colitis Mobilizes Copper from Latent Storage in the Liver into Systemic
Circulation

Figure 3.3 — Colitis induces mobilization of latent copper stored in the liver into
systemic circulation. First panel: liver concentrations of intracellular copper in mice over
the course of DSS treatment. p = 0.04. Second panel: serum copper concentrations mice
over the course of DSS treatment. p = 0.05. Day 0 represents the time at which the
animals’ drinking water was replaced by an aqueous 3% DSS solution. P-values reflect a
comparison between copper concentrations measured on day 0 and copper concentrations
measured on day 9. All copper measurements were done by GFAAS and each animal’s
sample was analyzed in triplicate. Error bars represent the standard deviation of each data
point. n = 3.
As has been mentioned previously, the liver is the largest storage site of copper in
the body [2]. While this has long been known, and it has also long been known that the
liver is a common site of colorectal cancer metastases, it has been believed that this is
primarily due to the high volume of blood flow from the intestines to the liver via the
hepatic portal vein, which provides a route of transportation of malignant cells from the
intestines to the liver. And while this is likely correct, it is suggested that the abundance
of copper may play a role in the success of intestinal cancer metastases in the liver as
well.
Upon reduction by a STEAP protein and uptake across the apical membrane into
an enterocyte by CTR1, the copper ion is immediately bound to one of several copper
chaperone proteins to prevent unwanted redox reactions from occurring within the cell.
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From there, depending on which protein the ion binds to, it is shuttled to one of several
locations – binding to COX17 delivers copper to the mitochondria, where it is
incorporated into cytochrome c oxidase, which is a crucial protein involved in cellular
respiration [88]. It may also be shuttled to the trans-Golgi network by ATOX1, where it
can be exported to the bloodstream by ATP7A or ATP7B, and then on to another
destination within the body [89]. A third important destination of the copper ions is the
cytosol of the enterocyte that initially took them up, where it can be shuttled by CCS to
superoxide dismutase (SOD1), a critical protein which converts intracellular superoxide
radicals (O2−) into molecular oxygen, and thus prevents unwanted radical-generating
reactions from occurring within the cell [90]. Excess intracellular copper may also be
bound to metallothionein. If the ion is exported to the bloodstream, it binds to α2macroglobulin or albumin and is taken up into a hepatocyte by CTR1. From there, it can
be transported to mitochondria or superoxide dismutase within the hepatocyte, or shuttled
to the trans-Golgi network and exported again to the bloodstream, where it binds to
ceruloplasmin or albumin, and is then distributed to cells and tissues around the body
[91].
It has been reported previously that elevated serum copper in mouse models of
breast and lung cancer occur concomitantly with a decrease in liver copper levels [92].
The data shown in Figure 3.3 indicate that this is the case in a mouse model of
inflammatory bowel disease as well. Copper, therefore, is being mobilized from the site
of storage into systemic blood circulation, which likely increases the risk of
tumorigenesis directly via the increased risk of oxidative DNA damage through Fenton
reaction-mediated production of reactive oxygen species at the site of inflammation, as
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well as indirectly by sustaining the chronic inflammatory response and resulting tumorpromoting environment at the site of inflammation. This also likely sustains tumor
progression as well by providing the copper necessary for continued cell growth and
angiogenesis. Therefore, it is suggested that copper depletion therapy may
simultaneously serve the dual functions of slowing the progression of a primary colon
tumor by depriving it of the resources necessary for growth, and may additionally
decrease the likelihood of a secondary tumor successfully establishing in the liver as well
due to less copper being available in the local environment
3.4 STEAP4 Overexpression Enhances IL-17-Mediated Activation of Growth
Pathways in Colon Cancer Cells

Figure 3.4 — STEAP4 overexpression enhances IL-17-mediated activation of
MAPK/ERK signaling in LS147T cells. Activation of ERK1/2 and ERK5 is increased in
doxycycline-treated cells compared to untreated cells. The relative intensity of each band
was quantified using ImageJ software. The intensities of the p-ERK1/2 and p-ERK5
bands from the zero timepoint from the treated cell group and the untreated cell group
were defined as 1 for each respective group. “Normalized relative intensity” was obtained
by dividing the intensity of each band by the intensity of the band from the zero timepoint
from its group, after the intensity value for each band had been normalized against the
intensity of its corresponding actin band.
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Colorectal carcinogenesis is a complex biological event involving dysregulation
of the growth, proliferation, and differentiation of enterocytes, as well as of pro-apoptotic
and cell survival mechanisms [93]. These cell cycle processes are regulated by a variety
of internal as well as external signals. External signals perform this regulation by binding
to cell membrane receptors and thus triggering the corresponding signaling cascade. One
significant example of these externally regulated signaling pathways is the mitogenactivated protein kinase/extracellular signal regulated-kinase, or MAPK/ERK pathway.
Being members of the serine-threonine kinase family, it has long been known that this
pathway is critical regulator of human gene expression and cellular proliferation [94].
Accordingly, the MAPK/ERK signaling cascade has previously been implicated in
several different types of cancers [95]. The ERK signaling pathway specifically, of three
known pathways falling under the MAPK family, is communicated through the activation
of Protein Kinase C, or PKC. PKC in turn activates RAF1, which then activates MEK.
MEK then activates ERK, which can then directly phosphorylate various transcription
factors, which themselves directly affect gene expression related to proliferation and cell
survival [96].
IL-17 signaling is known to activate several important cell growth and
proliferation pathways, including the PI3K-AKT and NF-κB pathways, in addition to the
ERK signaling cascade [97]. The data presented in Figure 3.4 demonstrates that this
activation of ERK signaling is enhanced by overexpression of STEAP4, suggesting that
copper plays an important role in this process. A previous report demonstrated that
deletion or mutation of copper transporter 1 (CTR1), as well as treatment with a copper
chelator, can inhibit this signaling pathway by reducing the ability of MEK1 to
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phosphorylate ERK [98], further substantiating this assertion. It is therefore suggested
that inhibiting IL-17 signaling and administering copper depletion therapy concurrently
could be more effective in retarding tumor progression than either treatment separately,
though further investigation into this assertion is recommended.
3.5 Copper Chelation as Potential Anti-Cancer Therapy and Future Directions

Figure 3.5 — Copper chelation potentially decreases the number of tumor nodules in
DSS-AOM mice. Animals were sacrificed by CO2 asphyxiation at the conclusion of the
third “recovery cycle” of unaltered drinking water, 8 weeks after AOM injection and the
beginning of the first DSS-treated drinking water cycle. Tumor nodules were identified
by visual inspection and were defined as any lesion on the colon measuring 1 mm in
diameter or larger. The “x” from each box signifies the median value for the group and
the line signifies the mean. n = 6. p = 0.16.
Given all of the data shown thus far, the practical question to ask is whether
copper depletion could be an effective treatment for inflammation-associated colorectal
cancer patients. Ammonium tetrathiomolybdate (TTM) is a copper chelator that is used
to treat Wilson’s Disease, a condition characterized by a defect in ATP7B that causes
excess copper accumulation in the liver and brain [99]. While TTM is currently only
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approved by the Food and Drug Administration for treatment of Wilson’s Disease
(administered orally in the form of capsule), it has very recently been reported that TTM
treatment inhibits inflammatory responses in microglia cells in vitro [100]. The molecule
is also currently being investigated as a therapy for breast cancer [101]. While the data
displayed in Figure 3.6 did not find a statistically significant difference in the
development of tumor nodules between the animals treated with the chelator and the
animals gavaged only with water, they do suggest that further study into whether or not
TTM is an effective treatment for colorectal cancer patients could be valuable.
While colorectal cancer can usually be treated relatively easily when detected
early, effective treatment of metastatic colon cancer remains a significant clinical
challenge with few good therapeutic options. While the five-year survival rate for
patients diagnosed with stage 1 through stage 3 colorectal cancer ranges from 92% to
53%, the rate for patients diagnosed with stage 4 of the disease stands at a dismal 11%
[102]. There is, therefore, an urgent need to find effective treatments for patients
diagnosed with metastatic colorectal cancer. As was mentioned earlier, the liver is the
most common site of metastasis for primary colon tumors, and is also the largest site of
copper storage in the body. Previous studies have reported that in mice which were
genetically programmed to develop breast cancer, copper depletion treatment did not
prevent the formation of tumors in the breast tissue, but animals treated with TTM
developed tumors that were too small to be observed visually, while untreated animals
developed easily visible tumors [103]. Therefore, it is recommended that additional
studies be performed to investigate the potential of copper depletion therapy to prevent
the growth of additional tumors after the initial one is discovered. It is likely that further
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investigation into this route of cancer treatment, in patients afflicted with colorectal and
other cancers will continue into the future.
3.6 Statistical Analysis
Pipette volumes were assumed to have a standard deviation of ±2%.
Tissue samples were massed to two decimal points of accuracy.
Statistical Calculations for Figure 3.1
Error in AAS measurements
∆[Cu] = [Cu]4 ℎ𝑟 − [Cu]0 ℎ𝑟
∆[Cu]𝑡𝑟𝑒𝑎𝑡𝑒𝑑 = 220.4820171 − 3.762017139 = 216.719999961

ng
mg protein

∆[Cu]𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 = 177.8407422 − 0.073274351 = 177.767467849

ng
mg protein

𝜎∆[Cu],𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 = √𝜎[Cu],0 ℎ𝑟 2 + 𝜎[Cu],4 ℎ𝑟 2
𝜎∆ [Cu],𝑡𝑟𝑒𝑎𝑡𝑒𝑑 = √𝜎 [Cu],𝑡𝑟𝑒𝑎𝑡𝑒𝑑,0 ℎ𝑟 2 + 𝜎 [Cu],𝑡𝑟𝑒𝑎𝑡𝑒𝑑,4 ℎ𝑟 2
0.086248476 2
0.096754824 2
𝜎∆[Cu],𝑡𝑟𝑒𝑎𝑡𝑒𝑑 = √(
) +(
) = 0.04320531806206
3
3

𝜎∆[Cu],𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 = √𝜎[Cu],𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑,0 ℎ𝑟 2 + 𝜎 [Cu],𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑,4 ℎ𝑟 2
0.081990144 2
0.103151556 2
𝜎∆[Cu],𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 = √(
) +(
) = 0.043922440756864
3
3

𝜎∆[Cu],𝑡𝑜𝑡𝑎𝑙 = √𝜎∆Cu,𝑡𝑟𝑒𝑎𝑡𝑒𝑑 2 + 𝜎∆Cu,𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 2
𝜎∆[Cu],𝑡𝑜𝑡𝑎𝑙 = √0.043205318062062 + 0.0439224407568642
𝜎∆[Cu,]𝑡𝑜𝑡𝑎𝑙 = 0.061610715877061
𝜎∆Cu,𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 = 0.061610715877061
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Error in sample volumes
𝜎𝑣𝑜𝑙𝑢𝑚𝑒

=

[Cu]𝑡𝑟𝑒𝑎𝑡𝑒𝑑,0ℎ𝑟 [Cu]𝑡𝑟𝑒𝑎𝑡𝑒𝑑,0ℎ𝑟 2
[Cu]𝑡𝑟𝑒𝑎𝑡𝑒𝑑,4ℎ𝑟 [Cu]𝑡𝑟𝑒𝑎𝑡𝑒𝑑,4ℎ𝑟 2
(
−
) +(
−
) +
vol + σ
vol
vol + σ
vol
[Cu]𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑,0ℎ𝑟 [Cu]𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑,0ℎ𝑟 2
[Cu]𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑,4ℎ𝑟 [Cu]𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑,4ℎ𝑟 2
(
−
) +(
−
)
vol + σ
vol
vol + σ
vol
√

𝜎𝑣𝑜𝑙𝑢𝑚𝑒
3.762017139 3.762017139 2
220.4820171 220.4820171 2
0.073274351
(
−
) +(
−
) +(
1.02
1
1.02
1
1.02
=
0.073274351 2
177.8407422 177.8407422 2
−
) +(
−
)
√
1
1.02
1

𝜎𝑣𝑜𝑙𝑢𝑚𝑒 = 5.6658110888888

Total error
𝜎𝑡𝑜𝑡𝑎𝑙 = √𝜎𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑐𝑒 2 + 𝜎𝑣𝑜𝑙𝑢𝑚𝑒 2
𝜎𝑡𝑜𝑡𝑎𝑙 = √0.0616107158770612 + 5.66581108888882
𝜎𝑡𝑜𝑡𝑎𝑙 = 5.6661460601794

t=
t=

∆[Cu]𝑡𝑟𝑒𝑎𝑡𝑒𝑑 − ∆[Cu]𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑
𝜎𝑡𝑜𝑡𝑎𝑙
216.719999961 − 177.8407422
5.6661460601794
t = 6.86167588129

p = 0.04

Statistical Calculations for Figure 3.2
Error in AAS measurements
∆[Cu]𝑡𝑟𝑒𝑎𝑡𝑒𝑑 = 419.7013339 − 10.62239755 = 409.07893635
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ng
mg protein

∆[Cu]𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 = 237.0232717 − 42.67507704 = 194.34819466

ng
mg protein

𝜎∆[Cu],𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 = √𝜎[Cu]0 ℎ𝑟 2 + 𝜎[Cu]4 ℎ𝑟 2
0.0768144 2
0.971792 2
𝜎∆ [Cu],𝑡𝑟𝑒𝑎𝑡𝑒𝑑 = √(
) +(
) = 0.325000858261
3
3
0.0424896 2
0.7554624 2
𝜎∆ [Cu],𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 = √(
) +(
) = 0.25221877715
3
3

𝜎∆[Cu],𝑡𝑜𝑡𝑎𝑙 = √𝜎∆[Cu],𝑡𝑟𝑒𝑎𝑡𝑒𝑑 2 + 𝜎∆[Cu],𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 2
𝜎∆[Cu],𝑡𝑜𝑡𝑎𝑙 = √0.3250008582612 + 0.252218777152
𝜎∆[Cu],𝑡𝑜𝑡𝑎𝑙 = 0.411387736105

ng
mg protein

Error in sample volumes
Sample volume = 300 μL lysate + 700 μL acid = 1 mL
Sample volume SD = 6 μL lysate + 14 μL acid = 20 μL

𝜎𝑣𝑜𝑙𝑢𝑚𝑒

=

[Cu]𝑡𝑟𝑒𝑎𝑡𝑒𝑑,0ℎ𝑟 [Cu]𝑡𝑟𝑒𝑎𝑡𝑒𝑑,0ℎ𝑟 2
[Cu]𝑡𝑟𝑒𝑎𝑡𝑒𝑑,4ℎ𝑟 [Cu]𝑡𝑟𝑒𝑎𝑡𝑒𝑑,4ℎ𝑟 2
(
−
) + ([
−
) +
vol + σ
vol
vol + σ
vol
[Cu]𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑,0ℎ𝑟 [Cu]𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑,0ℎ𝑟 2
[Cu]𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑,4ℎ𝑟 [Cu]𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑,4ℎ𝑟 2
(
−
) +(
−
)
vol + σ
vol
vol + σ
vol
√

𝜎𝑣𝑜𝑙𝑢𝑚𝑒
10.62239755 10.62239755 2
419.7013339 419.7013339 2
42.67507704
(
−
) +(
−
) +(
1.02
1
1.02
1
1.02
=
42.67507704 2
237.0232717 237.0232717 2
−
) +(
−
)
√
1
1.02
1
𝜎𝑣𝑜𝑙𝑢𝑚𝑒 = 9.4903427013242
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Total error
𝜎𝑡𝑜𝑡𝑎𝑙 = √𝜎𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑐𝑒 2 + 𝜎𝑣𝑜𝑙𝑢𝑚𝑒 2
𝜎𝑡𝑜𝑡𝑎𝑙 = √0.4113877361052 + 9.49034270132422
𝜎𝑡𝑜𝑡𝑎𝑙 = 9.4992549422571

t=
t=

∆[Cu]𝑡𝑟𝑒𝑎𝑡𝑒𝑑 − ∆[Cu]𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑
𝜎𝑡𝑜𝑡𝑎𝑙
409.07893635 − 194.34819466
9.4992549422571
t = 22.5263157895

p = 0.01

Statistical Calculations for Figure 3.3 (A)
Error in AAS measurements
𝜎[Cu,𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝑡𝑖𝑚𝑒𝑝𝑜𝑖𝑛𝑡𝑠]

𝜎[Cu],𝐷𝑎𝑦 0,𝑝𝑜𝑖𝑛𝑡1 2 + 𝜎[Cu],𝐷𝑎𝑦 9,𝑝𝑜𝑖𝑛𝑡2 2 + 𝜎[Cu],𝐷𝑎𝑦 9,𝑝𝑜𝑖𝑛𝑡1 2 +
= √
𝜎[Cu],𝐷𝑎𝑦 9,𝑝𝑜𝑖𝑛𝑡2 2 + 𝜎[Cu],𝐷𝑎𝑦 9,𝑝𝑜𝑖𝑛𝑡3 2

𝜎[Cu,𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝑡𝑖𝑚𝑒𝑝𝑜𝑖𝑛𝑡𝑠]
6.73𝑥10−5 2
6.7𝑥10−5 2
3.42𝑥10−6 2
5.6𝑥10−6 2
3.8𝑥10−5 2
= √(
) + (
) + (
) + (
) +(
)
3
3
3
3
3
𝜎[Cu,𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝑡𝑖𝑚𝑒𝑝𝑜𝑖𝑛𝑡𝑠] = 0.0000341651973668
𝜎[Cu,𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒,𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑖𝑚𝑒𝑝𝑜𝑖𝑛𝑡𝑠] = √𝜎[Cu],𝐷𝑎𝑦 0 2 + 𝜎[Cu],𝐷𝑎𝑦 9 2
0.385 2
1.199834 2
𝜎[Cu,𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑖𝑚𝑒𝑝𝑜𝑖𝑛𝑡𝑠] = √(
) +(
)
2
3
𝜎[Cu,𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑖𝑚𝑒𝑝𝑜𝑖𝑛𝑡𝑠] = 0.4438660323069
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𝜎[Cu,𝑡𝑜𝑡𝑎𝑙] = √𝜎[Cu],𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝑡𝑖𝑚𝑒𝑝𝑜𝑖𝑛𝑡𝑠 2 + 𝜎[Cu,]𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑖𝑚𝑒𝑝𝑜𝑖𝑛𝑡𝑠 2
𝜎[Cu,𝑡𝑜𝑡𝑎𝑙] = √0.00003416519736682 + 0.44386603230692
𝜎[Cu],𝑡𝑜𝑡𝑎𝑙 = 0.443866033622
𝜎[Cu],𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 = 0.443866033622

Error in sample volumes
Sample volume = 100 μL liver homogenate + 900 acid = 1 mL
Sample volume SD = 2 uL + 18 uL = 20 uL

𝜎𝑣𝑜𝑙𝑢𝑚𝑒

[Cu]𝐷𝑎𝑦 0,𝑝𝑜𝑖𝑛𝑡1 [Cu]𝐷𝑎𝑦 0,𝑝𝑜𝑖𝑛𝑡1 2
[Cu]𝐷𝑎𝑦 0,𝑝𝑜𝑖𝑛𝑡2 [Cu]𝐷𝑎𝑦 0,𝑝𝑜𝑖𝑛𝑡2 2
(
−
) +(
−
)
vol + σ
vol
vol + σ
vol
[Cu]𝐷𝑎𝑦 9,𝑝𝑜𝑖𝑛𝑡1 [Cu]𝐷𝑎𝑦 9,𝑝𝑜𝑖𝑛𝑡1 2
[Cu]𝐷𝑎𝑦 9,𝑝𝑜𝑖𝑛𝑡2
=
+(
−
) +(
vol + σ
vol
vol + σ
[Cu]𝐷𝑎𝑦 9,𝑝𝑜𝑖𝑛𝑡2 2
[Cu]𝐷𝑎𝑦 9,𝑝𝑜𝑖𝑛𝑡3 [Cu]𝐷𝑎𝑦 9,𝑝𝑜𝑖𝑛𝑡3 2
−
) +(
−
)
vol
vol + σ
vol
√

(
𝜎𝑣𝑜𝑙𝑢𝑚𝑒 =
√

4.8895 4.8895 2
5.6595 5.6595 2
3.5651 3.5651 2
−
) +(
−
) +(
−
)
1.02
1
1.02
1
1.02
1
1.1088 1.1088 2
0.9394 0.9394 2
+(
−
) +(
−
)
1.02
1
1.02
1
𝜎𝑣𝑜𝑙𝑢𝑚𝑒 = 0.16823673595265

Error in measurement of liver tissue mass
Mean tissue samples mass =

0.53 + 0.46 + 0.57 + 0.49 + 0.52
5

Mean tissue sample mass = 0.514 g
Balance error = ± 0.005 g
Average % error in tissue mass measurement =

0.01
0.514

Average % error in tissue mass measurement = 0.01945525291
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𝜎𝑣𝑜𝑙𝑢𝑚𝑒+𝑚𝑎𝑠𝑠 = 𝜎𝑣𝑜𝑙𝑢𝑚𝑒 𝑥 1.01945525291
𝜎𝑣𝑜𝑙𝑢𝑚𝑒+𝑚𝑎𝑠𝑠 = 0.16823673595265 𝑥 1.01945525291
𝜎𝑣𝑜𝑙𝑢𝑚𝑒+𝑚𝑎𝑠𝑠 = 0.17150982419

Total error

𝜎𝑡𝑜𝑡𝑎𝑙 = √𝜎𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑐𝑒 2 + 𝜎𝑣𝑜𝑙𝑢𝑚𝑒+𝑚𝑎𝑠𝑠 2
𝜎𝑡𝑜𝑡𝑎𝑙 = √0.4438660336222 + 0.171509824192
𝜎𝑡𝑜𝑡𝑎𝑙 = 0.47584942534063

t=

(5.2745 − 1.8711)
0.47584942534063

t = 7.15226249893

p = 0.04

Statistical Calculations for Figure 3.3 (B)
Error in AAS measurements
𝜎[Cu,𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝑡𝑖𝑚𝑒𝑝𝑜𝑖𝑛𝑡𝑠]

𝜎[Cu],𝐷𝑎𝑦 0,𝑝𝑜𝑖𝑛𝑡1 2 + 𝜎[Cu],𝐷𝑎𝑦 9,𝑝𝑜𝑖𝑛𝑡2 2 + 𝜎[Cu],𝐷𝑎𝑦 9,𝑝𝑜𝑖𝑛𝑡1 2 +
= √
𝜎[Cu],𝐷𝑎𝑦 9,𝑝𝑜𝑖𝑛𝑡2 2 + 𝜎[Cu],𝐷𝑎𝑦 9,𝑝𝑜𝑖𝑛𝑡3 2

𝜎[Cu,𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝑡𝑖𝑚𝑒𝑝𝑜𝑖𝑛𝑡𝑠]
1.767745 2
0.062935 2
0.13995 2
0.145203 2
0.132101 2
= √(
) + (
) + (
) + (
) +(
)
3
3
3
3
3
𝜎[Cu,𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝑡𝑖𝑚𝑒𝑝𝑜𝑖𝑛𝑡𝑠] = 0.595097445145

𝜎[Cu,𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑖𝑚𝑒𝑝𝑜𝑖𝑛𝑡𝑠] = √𝜎[Cu],𝐷𝑎𝑦 0 2 + 𝜎[Cu],𝐷𝑎𝑦 9 2
2.17865 2
10.60767 2
𝜎[Cu,𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑖𝑚𝑒𝑝𝑜𝑖𝑛𝑡𝑠] = √(
) +(
)
2
3
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𝜎[Cu,𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑖𝑚𝑒𝑝𝑜𝑖𝑛𝑡𝑠] = 3.69988473438

𝜎[Cu,𝑡𝑜𝑡𝑎𝑙] = √𝜎[Cu],𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝑡𝑖𝑚𝑒𝑝𝑜𝑖𝑛𝑡𝑠 2 + 𝜎[Cu],𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑖𝑚𝑒𝑝𝑜𝑖𝑛𝑡𝑠 2
𝜎[Cu,𝑡𝑜𝑡𝑎𝑙] = √0.5950974451452 + 3.699884734382
𝜎[Cu],𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒,𝑡𝑜𝑡𝑎𝑙 = 3.74743752675

Error in sample volumes
Sample volume = 100 μL serum + 900 μL acid = 1 mL
Sample volume SD = 6 μL lysate + 14 μL acid = 20 μL

𝜎𝑣𝑜𝑙𝑢𝑚𝑒

[Cu]𝐷𝑎𝑦 0,𝑝𝑜𝑖𝑛𝑡1 [Cu]𝐷𝑎𝑦 0,𝑝𝑜𝑖𝑛𝑡1 2
[Cu]𝐷𝑎𝑦 0,𝑝𝑜𝑖𝑛𝑡2
(
−
) +(
−
vol + σ
vol
vol + σ
[Cu]𝐷𝑎𝑦 9,𝑝𝑜𝑖𝑛𝑡1 [Cu]𝐷𝑎𝑦 9,𝑝𝑜𝑖𝑛𝑡1
[Cu]𝐷𝑎𝑦 0,𝑝𝑜𝑖𝑛𝑡2 2
=
) +(
−
)2 +
vol
vol + σ
vol
[Cu]𝐷𝑎𝑦 9,𝑝𝑜𝑖𝑛𝑡2 [Cu]𝐷𝑎𝑦 9,𝑝𝑜𝑖𝑛𝑡2 2
[Cu]𝐷𝑎𝑦 9,𝑝𝑜𝑖𝑛𝑡3 [Cu]𝐷𝑎𝑦 9,𝑝𝑜𝑖𝑛𝑡3 2
−(
−
) +(
−
)
vol + σ
vol
vol + σ
vol
√

𝜎𝑣𝑜𝑙𝑢𝑚𝑒 =

52.7685 52.7685 2
48.4112 48.4112 2
116.625 116.625 2
(
−
) +(
−
) +(
−
)
1.02
1
1.02
1
1.02
1
√

90.752 90.752 2
101.6165 101.6165 2
+(
−
) +(
−
)
1.02
1
1.02
1
𝜎𝑣𝑜𝑙𝑢𝑚𝑒 = 3.8621956490546

Total error
𝜎𝑡𝑜𝑡𝑎𝑙 = √𝜎𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑐𝑒 2 + 𝜎𝑣𝑜𝑙𝑢𝑚𝑒 2
𝜎𝑡𝑜𝑡𝑎𝑙 = √3.747437526752 + 3.8621956490546 2
𝜎𝑡𝑜𝑡𝑎𝑙 = 9.4992549422571

t=

(102.9978333 − 50.58985)
9.4992549422571
t = 5.51706250844
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p = 0.05

Statistical Calculations for Figure 3.5
Avg # of tumor nodules𝑡𝑟𝑒𝑎𝑡𝑒𝑑 = 1
Avg # of tumor nodules𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 = 2.5

𝜎𝑡𝑟𝑒𝑎𝑡𝑒𝑑 = 1.095445
𝜎𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 = 1.760682

𝜎𝑡𝑜𝑡𝑎𝑙 = √𝜎𝑡𝑟𝑒𝑎𝑡𝑒𝑑 2 + 𝜎𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 2
𝜎𝑡𝑜𝑡𝑎𝑙 = √1.0954452 + 1.7606822
𝜎𝑡𝑜𝑡𝑎𝑙 = 2.07354434105

t=

(2.5 − 1)
2.07364434105
(
)
√6

t = 1.77187309388

p = 0.16
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CHAPTER IV
CONCLUSION
Despite encouraging progress that has been made, colorectal cancer remains a
significant clinical challenge. This is particularly true in patients who do not regularly
receive colonoscopies, as the disease becomes significantly more difficult to treat
effectively in its later stages. Despite the American Cancer Society’s recommendation
that adults aged 45 years or older get screened for colorectal cancer, fully one-third of
adults 50 to 75 years of age have never received a colonoscopy [104]. For this reason, a
better understanding of the pathogenesis of colorectal cancer and new treatment options,
particularly for metastatic tumors, is urgently needed.
It has long been known that chronic inflammation increases an individual’s risk of
developing colorectal cancer [32]. While inflammation is a remarkably complex
biological response, it is known that interleukin 17 is a critical mediator of the
inflammatory process. Thus, IL-17 is a promising target for anti-cancer therapies that has
been investigated for many years now [78]. The precise role that IL-17, and
inflammation generally plays in tumorigenesis and tumor progression is still not fully
understood. Data presented in this thesis suggest that the pro-inflammatory and the
cancer-promoting properties of IL-17 are dependent, at least in part, on copper.
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G

H

Figure 4.1 – A proposed visual model of IL-17’s effects on copper mobilization and tumor promotion. The colon is represented in
blue, the liver is represented in brown, STEAP4 is represented in purple, and copper ions are represented in green. A) The liver and
colon are healthy and normal, and STEAP4 is expressed normally in colon epithelial cells. B) The colon epithelium suffers and injury
(represented in red). C) The injury to the colon tissue causes Paneth cells and white blood cells from the local blood supply to begin
secreting IL-17 (represented in crimson). D) IL-17-mediated inflammation causes latent copper stored in the liver to be mobilized into
systemic circulation. IL-17 stimulation additionally induces increased expression of STEAP4 by colon epithelial cells. This
overexpression of STEAP4 causes colon epithelial cells to increase the amount of copper they take up from the blood. E) IL-17
signaling causes increased ERK signaling (represented in gold) in colon epithelial cells, promoting cell survival and increasing cell
growth and proliferation, and thus the risk of tumorigenesis (represented in yellow). F) IL-17 signaling further upregulates the
expression of STEAP4 in colon carcinoma cells. G) Continued inflammation, mediated by IL-17, continues to mobilize copper from
the liver into systemic circulation, which further increases activation of ERK signaling, as the STEAP4-overexpressed cells take up
additional copper from the blood, thus fueling a positive feedback cycle. H) After tumorigenesis, the established tumor causes
dysregulation of normal colon homeostasis, thus sustaining a pro-inflammatory environment in the colon, paving the way for
continued tumor growth and metastasis to potentially occur.
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A crucial element in biology, copper is a required element in all living systems
due to its ability to participate in one-electron transfer reactions. In humans, the ability of
cells to take up copper from their extracellular requirement is dependent on a family of
proteins known as the Six Transmembrane Epithelial Antigen of Prostate, or STEAP
proteins. Additionally, it has previously been reported that copper is often elevated in
malignant tissue samples compared to corresponding healthy tissue, including those
found in colon cancer [75]. Previous data from the Li lab revealed that increased
expression of STEAP4 is induced by stimulation with IL-17 [76]. Data from experiments
presented in this thesis show that both overexpression of STEAP4, and stimulation with
IL-17 increases the amount of copper taken up by colorectal cancer cells, the rate of
which in the latter case agrees with data previously reported in human embryonic kidney
cells [13]. Further data indicate that overexpression of STEAP4 in colon cancer cells
enhances activation of the ERK pathway, which has previously been implicated in
colorectal cancer [38], by IL-17 stimulation, suggesting that copper plays a critical role in
this signaling process.
The most common site of distant colorectal cancer metastases is the liver. Upon
the occurrence of colon cancer metastasis to the liver, the disease’s prognosis becomes
dismal [102]. Data presented here suggest that upon induction of intestinal inflammation,
copper is mobilized from the liver into systemic circulation, which agrees with data
previously reported indicating that this occurs in a mouse model of breast cancer as well
[92]. Additionally, it was found that treatment with the copper chelator ammonium
tetrathiomolybdate, used to treat copper overload in Wilson’s Disease, potentially reduces
the number of tumor nodules that develop in the colon in a model of inflammation64

associated colorectal cancer, though further investigation is required to provide
convincing evidence of this conclusion. It is suggested that copper depletion therapy
could slow the growth of colorectal tumors, and possibly reduce the instances of tumor
metastases. Further study into this avenue of treatment is suggested.
The progress that has been made into describing the mechanisms of colon
tumorigenesis and tumor progression, particularly in the context of an inflammatory
microenvironment, has been encouraging. However, for people afflicted with the
condition, it is still not enough. It is the author’s hope that the experiments presented
herein that detail the copper-dependent role of IL-17 in colorectal cancer cell growth will
provide another step on the road to understanding, and ultimately curing, this devastating
disease.
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Figure 1.3 – A schematic description of STEAP4’s protein structure and
molecular functions
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Figure 1.5 – MAPK/ERK signaling in the pathogenesis of cancer
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Figure 1.6 – Immune system signaling and inflammation play a critical role in the
risk of tumorigenesis and cancer progression.
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Figure 1.7 – IL-17 increases expression of many genes through activation of
various downstream signaling pathways.
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